ArticleFrontiers in neurology2022
Annual Trends in the Incidence and Prevalence of Alzheimer's Disease in South Korea: A Nationwide Cohort Study.
Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Role of Physical Activity in Protecting Against Dementia According to Menopausal Status.Journal of clinical neurology (Seoul, Korea) · 2026Article
- The Intersection of Physical Inactivity, Dementia, and Gender: A Population-Based Study of All-Cause Mortality in Middle-Aged and Older Adults in Korea.Medicina (Kaunas, Lithuania) · 2026Article
- Dietary Isoflavone Biochanin A Attenuates Aluminium Chloride-Induced Sporadic Alzheimer's Disease and Associated Neurobehavioral Alterations Through NRF2-HO1 Pathway Activation and NLRP3 Inflammasome Suppression.Molecular neurobiology · 2026Article
- The Gwangju Alzheimer's & Related Dementias (GARD) cohort: Over a decade of Asia's largest longitudinal multimodal study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Thirty-seven-year trends in the prevalence, incidence, and prognosis of dementia in a Japanese community: the Hisayama study.Alzheimer's research & therapy · 2025Article
- Neuroprotective Effects of Human Adipose Tissue-Derived Mesenchymal Stromal Cells Against Radiation-Induced Neural Damage : A Comparative In Vitro Study.Journal of Korean Neurosurgical Society · 2025Article
- Use of Amyloid Positron-Emission Tomography to Diagnose Alzheimer's Disease in Clinical Practice in South Korea: Expert Recommendations.Journal of clinical neurology (Seoul, Korea) · 2025Review
- Longitudinal trends in dementia prevalence among individuals with type 2 diabetes in Taiwan (2009-2022).Journal of diabetes investigation · 2025Article
- Alzheimer Disease in Breast Cancer Survivors.JAMA network open · 2025Article
- Article
- Impact of nucleos(t)ide analogue therapy on the incidence of Alzheimer's disease in patients with chronic hepatitis B virus infection.Alzheimer's research & therapy · 2025Article
- Efficacy of Human-Induced Pluripotent Stem Cell-Derived Neural Progenitor Cell Replacement Therapy in a Vascular Dementia Animal Model.Tissue engineering and regenerative medicine · 2025Article
- Association between dementia diagnosis at dialysis initiation and mortality in older patients with end-stage kidney disease in South Korea.Kidney research and clinical practice · 2025Article
- Emerging evidence that ginseng components improve cognition in subjective memory impairment, mild cognitive impairment, and early Alzheimer's disease dementia.Journal of ginseng research · 2024Review
- Association between migraine and the risk of vascular dementia: A nationwide longitudinal study in South Korea.PloS one · 2024Article
- Preliminary study on the feasibility of virtual reality-based cognitive training on patients with mild to moderate Alzheimer's disease.Journal of Alzheimer's disease reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite recent studies suggesting a declining incidence and prevalence of dementia on a global scale, epidemiologic results with respect to Alzheimer's disease (AD) are lacking due to the methodological limitations inherent to conducting large-scale cohort investigations of this topic. The aim of the current study was to investigate the incidence and prevalence of AD in Korea. We conducted a secondary analysis within the National Health Insurance System (NHIS) database, a unique resource that reports medical information for the entire Korean population. AD diagnoses as well as evaluations of vascular risks were defined based on International Statistical Classification of Diseases (ICD-10) codes along with prescription records. The cut-off age for diagnosing AD was defined as the age of the patient's highest Youden index. In this study, the incidence and prevalence of AD in the Korean population aged 40 years or older showed an overall increase between 2006 and 2015. Although both older and younger age groups showed an increase in the incidence and prevalence of AD, the highest increase was observed in older age groups. Based on the highest Youden's index value (sensitivity + specificity - 1), the cut-off value for the diagnosis of AD was 69 years with an area under the curve (AUC) of 0.92. We found that the incidence of AD was higher in individuals with underlying vascular risks. However, in recent years, the prevalence of AD was conversely found to be lower in individuals with hypertension or dyslipidemia. Despite efforts toward reducing the number of AD cases through educational, policy, and various public health and preventive medicine interventions, the incidence and prevalence of AD continues to grow in Korea. Efforts aimed at early diagnosis and the modification of underlying risks may be critical to reducing the socioeconomic burden of AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.